Navigation Links
Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Date:2/6/2012

RESEARCH TRIANGLE PARK, N.C., Feb. 6, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients. CMX001 is a broad spectrum Lipid-Antiviral-Conjugate completing Phase 2 clinical development for the prevention of CMV in HCT recipients. In CMX001 Study 201, a double-blind, placebo-controlled trial which enrolled 230 HCT recipients, CMX001 had a statistically significant benefit versus placebo in preventing CMV viremia and/or CMV disease 13 weeks post-transplant.

Francisco Marty, MD, Assistant Professor of Medicine at Dana-Farber Cancer Institute and Brigham and Women's Hospital's Division of Infectious Disease, and a lead investigator in Chimerix's CMX001 Phase 2 CMV study, presented the data during the "Best Abstracts Plenary Session" at the 2012 BMT Tandem Meetings on February 3, 2012 in San Diego, California. "This study provides positive data supporting the antiviral activity of CMX001 at different dose levels, and a better understanding of CMX001's safety and tolerability as a prophylactic agent against CMV infection, a major cause of morbidity and mortality in bone marrow transplant recipients," said Dr. Marty.  "There is a substantial unmet medical need for safer and effective therapies against CMV. If approved, many patients have the potential to benefit from the future availability of CMX001."

"These results exceeded our high expectations, and we are thrilled to share such positive CMX001 data with the transplant community," said Wendy P. Painter, MD, MPH, Chimerix's Chief Medical Officer. "We look forward to initiating the Phase 3 CMV program later this year. This study reinforces our belief that CMX001's broad spectrum application against multiple viral infections, its safety profile
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
2. Chimerix Joins International Network of Organizations to Cure Malaria
3. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
4. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
5. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
6. Chimerix Initiates Phase 1 Study of CMX157
7. Chimerix to Present at Upcoming Investor Conferences
8. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
9. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
10. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
11. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... MA (PRWEB) May 19, 2013 The ... social media training online, has proudly announced that the ... small business has surpassed 175,000 views on YouTube. The ... social media and SEO tips and training for small ... my students find the YouTube tips helpful for their ...
(Date:5/17/2013)... German . ... eye, you can see which branch a bird is sitting ... through the telephoto lens for high-magnification images requires considerable skill. ... to study proteins, the active biomolecules of cells. , Olga ... Systems Biology, and her colleagues have now come up with ...
(Date:5/17/2013)... PALO ALTO, Calif. , May 17, 2013 ... that it has achieved 50% enrollment of the ... trial to evaluate the safety and preliminary efficacy ... Progenitor Cells) therapy for Knee Osteoarthritis (KOA). To ... Effect (SAE) reported. The Phase I ...
(Date:5/17/2013)... The paradigm of ‘one drug, one ... can help predict the adverse and therapeutic effects of ... of Computational Biology at the Genomics Laboratory, Covance, will ... high-quality genomics when used as part of the QC ... data sets to identify key clinical targets even in ...
Breaking Biology Technology:YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group 2Proteome atlas for the tuberculosis pathogen 2Proteome atlas for the tuberculosis pathogen 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2
... RESEARCH TRIANGLE PARK, N.C., Jan. 9 Quintiles,Transnational ... its,Global Central Laboratories and Clinical Development Services (CDS) ... China., The new consolidated Quintiles China facility, ... located at Sun Dong Ann Plaza in Beijing, ...
... Burrill Merchant Banking acted as,exclusive financial advisor ... (teduglutide) with Nycomed.,Under the terms of the agreement, ... to Nycomed for the treatment of gastrointestinal disorders., ... for the treatment of,short-bowel syndrome (SBS). SBS can ...
... MATEO, Calif., Jan. 9 NeurogesX, Inc.,(Nasdaq: NGSX ... therapies, today announced that it completed a $25.0,million private ... of,its late stage portfolio of novel pain management therapies., ... on Sunday, December,23, 2007, it entered into a securities ...
Cached Biology Technology:Quintiles Central Lab, Clinical Development in China to Expand, Relocate to New Facility 2Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement 2NeurogesX Closes $25 Million Private Placement 2NeurogesX Closes $25 Million Private Placement 3NeurogesX Closes $25 Million Private Placement 4
(Date:5/17/2013)... Sustainable Global Logistics Operations) is aiming to cut CO2 ... intermodal loading systems and the boosting of intelligent systems ... with experience in the logistics sector and in supply ... a duration of three and a half years. , ... components and ontologies shared by the users, objects and ...
(Date:5/16/2013)... 2013) Illustrating a commitment to the support ... Association (AGA) Research Foundation has announced the inaugural ... Award recipients. Supported by the National Institute of ... new award helps underrepresented minority students to further ... research. , "By establishing this new award, AGA ...
(Date:5/16/2013)... scientists have used ancient shorelines to predict the stability of ... a high shoreline from three million years ago, for example ... were thought to be evidence of a high sea level ... has led many scientists to think that if the world,s ... do just the same in our modern, progressively warming world. ...
Breaking Biology News(10 mins):New logistics services that will cut energy consumption and CO2 emissions 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2World's biggest ice sheets likely more stable than previously believed 2
... While studying how a cell keeps its genetic material intact, ... two catalysts vital to managing a yeast cell's energy. They ... of them led the cell to turn off 70 percent ... unprepared for such a dramatic event," says Jef Boeke, Ph.D., ...
... A new study reveals how the production of a ... in natural killer (NK) cells, immune cells that typically ... IFNg, produced by NK cells and other cell types, ... in defending against tumor cells. However, overproduction of IFNg ...
... Massachusetts General Hospital (MGH) researchers have identified potential ovarian ... of treating these tumors with standard chemotherapy. Understanding ... lead to new approaches to treating ovarian cancer, which ... their fifth most common cause of cancer death. The ...
Cached Biology News:Johns hopkins researchers find link between cell's energy use and genome health 2Johns hopkins researchers find link between cell's energy use and genome health 3Research reveals control of potent immune regulator 2Mass. General study finds potential ovarian cancer stem cells 2
...
Jak3 Antibody Ship: Hot Store: -20 C...
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Applications: Western blotting Stability: Room temperature, indefinitely ...
Biology Products: